![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AZ’s Tagrisso Soars in Phase 3
AZ’s Tagrisso Soars in Phase 3
AstraZeneca’s lung cancer candidate Tagrisso succeeded in a Phase 3 trial, reaching its primary endpoint of superior progression-free survival versus standard platinum-based doublet chemotherapy.
The 400-patient trial assessed the drug in patients with EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer.
The drug was tested as a second-line treatment option if the cancer continues to progress following tyrosine kinase inhibitor therapy.
Upcoming Events
-
21Oct